Charles Schwab Investment Management Inc. Sells 10,372 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Charles Schwab Investment Management Inc. decreased its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 9.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 100,348 shares of the specialty pharmaceutical company’s stock after selling 10,372 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in KalVista Pharmaceuticals were worth $850,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. State Street Corp raised its stake in shares of KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after purchasing an additional 515,179 shares during the last quarter. Geode Capital Management LLC grew its holdings in KalVista Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock worth $9,624,000 after buying an additional 24,713 shares in the last quarter. Citigroup Inc. raised its position in KalVista Pharmaceuticals by 6.8% in the 3rd quarter. Citigroup Inc. now owns 305,504 shares of the specialty pharmaceutical company’s stock valued at $3,538,000 after buying an additional 19,440 shares during the last quarter. Readystate Asset Management LP bought a new position in KalVista Pharmaceuticals during the 3rd quarter valued at $2,084,000. Finally, Wellington Management Group LLP boosted its holdings in KalVista Pharmaceuticals by 40.3% during the 3rd quarter. Wellington Management Group LLP now owns 117,923 shares of the specialty pharmaceutical company’s stock worth $1,366,000 after acquiring an additional 33,900 shares during the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 6,669 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $11.97, for a total value of $79,827.93. Following the transaction, the chief executive officer now owns 287,811 shares of the company’s stock, valued at approximately $3,445,097.67. This represents a 2.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of KalVista Pharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $30,687.50. Following the transaction, the insider now owns 100,334 shares in the company, valued at $985,279.88. This represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 236,055 shares of company stock valued at $2,162,146 and have sold 17,292 shares valued at $184,625. Insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $11.93 on Monday. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $15.50. The stock’s 50 day simple moving average is $10.56 and its two-hundred day simple moving average is $10.25. The stock has a market cap of $593.11 million, a price-to-earnings ratio of -3.28 and a beta of 0.76.

Wall Street Analyst Weigh In

KALV has been the subject of several analyst reports. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Jones Trading reiterated a “buy” rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. TD Cowen assumed coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $24.83.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).